Overview

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Status:
Enrolling by invitation

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this open label extension study is to evaluate the long-term safety and tolerability of maralixibat.

Phase:

Phase 3

Details

Lead Sponsor:

Mirum Pharmaceuticals, Inc.